Epidural Dexamethasone for Labor Analgesia: the Effects on Ropivacaine Consumption and Labour Outcome (DEXAPER)
Primary Purpose
Obstetric Pain, Other Complications of Obstetric Anesthesia - Delivered
Status
Withdrawn
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Dexamethasone
Placebo
Ropivacaine
Sufentanil
Sponsored by
About this trial
This is an interventional treatment trial for Obstetric Pain
Eligibility Criteria
Inclusion Criteria:
- First and single pregnancy, Full term (> 37 wks amenorrhea), Cephalic presentation, Spontaneous labor, Epidural analgesia requested by the parturient
Exclusion Criteria:
- Minor patient, Planned cesarean section, Gestational hypertension and preeclampsia, Gestational diabetes, opioids or ocytocin administration before epidural analgesia preparation, Allergy to dexamethasone, Untreated gastroduodenal ulcer, epidural analgesia contraindications
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Epidural analgesia + DEXAMETHASONE
Epidural analgesia + PLACEBO
Arm Description
Single epidural injection of Dexamethasone Mylan (8 mg) concomitant to epidural analgesia (ropivacaine+ sufentanil)
Single epidural injection of sodium chloride (0.9%) Lavoisier concomitant to epidural analgesia (ropivacaine + sufentanil)
Outcomes
Primary Outcome Measures
Hourly ropivacaine consumption expressed as mg/mL used during epidural analgesia in parturient women
The administered dose of ropivacaine during epidural is used to measure the efficacy of Dexamethasone in reducing local anesthetics during labor analgesia
Secondary Outcome Measures
Improvement of epidural analgesia assessed by the reduction of adverse effects induced by local anesthetics
Adverse effects such as nausea and emesis, maternal hypotension, maternal hyperthermia will be recorded during epidural analgesia
Dexamethasone effect maternal pain during delivery assessed by Visual Analogic Scale
Evaluation of the lowered maternal pain induced by Dexamethasone
Improvement of delivery assessed by recording the number of side events (motor block, emergency cesarean, instrument-assisted delivery)
Rates of motor block, emergency cesarean, instrument-assisted delivery
Maternal satisfaction assessed by visual analogic scale
Patient satisfaction visual analogic scale
Full Information
NCT ID
NCT02857465
First Posted
July 26, 2016
Last Updated
March 6, 2019
Sponsor
Centre Hospitalier Universitaire de la Réunion
1. Study Identification
Unique Protocol Identification Number
NCT02857465
Brief Title
Epidural Dexamethasone for Labor Analgesia: the Effects on Ropivacaine Consumption and Labour Outcome
Acronym
DEXAPER
Official Title
Epidural Dexamethasone for Labor Analgesia: the Effects on Ropivacaine Consumption and Labour Outcome. A Randomized Double Blind Placebo Study
Study Type
Interventional
2. Study Status
Record Verification Date
March 2019
Overall Recruitment Status
Withdrawn
Why Stopped
French Agency for the Safety of Health Products refusal
Study Start Date
January 2017 (Anticipated)
Primary Completion Date
June 2017 (Actual)
Study Completion Date
June 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de la Réunion
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To assess the efficacy of epidural dexamethasone administration, compared to placebo, in reducing local anesthetics consumption during labor epidural analgesia in parturient women
Detailed Description
It is hypothesized that reducing the consumption of local anesthetics during labor epidural analgesia could lower their side effects (rate of motor block, nausea and emesis during labor, maternal hypotension, maternal fever) and improve the duration of the second part of the labor, and the new-born adaptation to child-birth and during the first 24 hours. The use of instruments for assisted vaginal delivery and the needs to perform emergency cesarean could also be impacted.
The efficacy of the dexamethasone will be assessed by the hourly Ropivacaine consumption (milligrams/hour) measured from randomization time to the end of epidural analgesia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstetric Pain, Other Complications of Obstetric Anesthesia - Delivered
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Epidural analgesia + DEXAMETHASONE
Arm Type
Experimental
Arm Description
Single epidural injection of Dexamethasone Mylan (8 mg) concomitant to epidural analgesia (ropivacaine+ sufentanil)
Arm Title
Epidural analgesia + PLACEBO
Arm Type
Placebo Comparator
Arm Description
Single epidural injection of sodium chloride (0.9%) Lavoisier concomitant to epidural analgesia (ropivacaine + sufentanil)
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Other Intervention Name(s)
Dexamethasone MYLAN
Intervention Description
single epidural injection of dexamethasone (8 mg) in addition to local anesthetics used for epidural analgesia
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Sodium chloride LAVOISIER 0.9 %
Intervention Description
single epidural injection of sodium chloride 0.9% (2 mL) in addition to local anesthetics used for epidural analgesia
Intervention Type
Drug
Intervention Name(s)
Ropivacaine
Other Intervention Name(s)
NAROPEINE 7.5 mg/ml, anhydrous ropivacaine chlorhydrate
Intervention Description
NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.
Intervention Type
Drug
Intervention Name(s)
Sufentanil
Other Intervention Name(s)
Sufentanil Mylan 0.5 microg/mL
Intervention Description
Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
Primary Outcome Measure Information:
Title
Hourly ropivacaine consumption expressed as mg/mL used during epidural analgesia in parturient women
Description
The administered dose of ropivacaine during epidural is used to measure the efficacy of Dexamethasone in reducing local anesthetics during labor analgesia
Time Frame
From the beginning to the end of epidural analgesia, that could last up to 6 hours
Secondary Outcome Measure Information:
Title
Improvement of epidural analgesia assessed by the reduction of adverse effects induced by local anesthetics
Description
Adverse effects such as nausea and emesis, maternal hypotension, maternal hyperthermia will be recorded during epidural analgesia
Time Frame
From the beginning to the end of epidural analgesia, that could last up to 6 hours
Title
Dexamethasone effect maternal pain during delivery assessed by Visual Analogic Scale
Description
Evaluation of the lowered maternal pain induced by Dexamethasone
Time Frame
From the beginning to the end of epidural analgesia, that could last up to 6 hours
Title
Improvement of delivery assessed by recording the number of side events (motor block, emergency cesarean, instrument-assisted delivery)
Description
Rates of motor block, emergency cesarean, instrument-assisted delivery
Time Frame
From the beginning to the end of epidural analgesia, that could last up to 6 hours
Title
Maternal satisfaction assessed by visual analogic scale
Description
Patient satisfaction visual analogic scale
Time Frame
On the morning of the next day after delivery, up to 24 hours
Other Pre-specified Outcome Measures:
Title
New-born adaptation to child-birth assessed by "Apgar score"
Description
Apgar score assessed twice: at 1 minute and 5 minutes after child-birth
Time Frame
up to 5 minutes after child-birth
Title
New-born adaptation to child-birth assessed by umbilical biochemical parameters
Description
Measurement of umbilical pH and lactates values at child-birth
Time Frame
umbilical blood collection up to 5 minutes after child-birth
Title
New-born adaptation to child-birth assessed by the rate of neonatal respiratory distress
Description
Rate of neonatal respiratory distress during the first 24 hours after child-birth
Time Frame
0-24 hours after child-birth
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
First and single pregnancy, Full term (> 37 wks amenorrhea), Cephalic presentation, Spontaneous labor, Epidural analgesia requested by the parturient
Exclusion Criteria:
Minor patient, Planned cesarean section, Gestational hypertension and preeclampsia, Gestational diabetes, opioids or ocytocin administration before epidural analgesia preparation, Allergy to dexamethasone, Untreated gastroduodenal ulcer, epidural analgesia contraindications
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Epidural Dexamethasone for Labor Analgesia: the Effects on Ropivacaine Consumption and Labour Outcome
We'll reach out to this number within 24 hrs